Home Patent Forecast® Sectors Log In   Contact  
How it works Patent Forecast® Sectors Pricing Insights

Application US20220031635
Wsmef Llc

Treating Covid 19 By Using A Mixture Of Cannabinoids In Micellized Form To Lower Levels Of Pro-inflammatory Cytokines And Reduce Risk Of Cytokine Storm

This disclosure provides a technology for managing elevated cytokine levels and the risk of cytokine storm in viral infection, exemplified by SARS-CoV-2, the virus that causes COVID-19. A special mixture of cannabidiol (CBD), tetrahydrocannabivarin (THCV), and cannabidivarin (CBDV) is extracted from the flowers and leaves ofCannabis sativa(industrial hemp). The purified oil is packed with a surfactant into small micelles, which considerably increases absorption by the gastrointestinal tract, resulting in higher potency and a more rapid onset of action. Daily treatment of patients infected with SARS-CoV-2 reduces the circulating level of the pro-inflammatory cytokines tumor necrosis factor alpha (TNFα) and interleukin 6 (IL-6) by 25 to 50% or more. The level of circulating markers of ongoing inflammation, such as C reactive protein (CRP) and/or erythrocyte sedimentation rate (EST) are also reduced. This lowers the risk that the treated patient will suffer the adverse consequences of a cytokine storm, potentially helping the patient to clear the virus and return to good health.

Much More than Average Length Specification

1 Independent Claims

View Abstract and Specification Size

PDF with Images and Document Face >

Full Text Publication >

Patent Matrix® Search

USPTO Patent Document Number